Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week.
Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.
When Helene Brown, a cancer control pioneer who jokingly described herself as “the first in a long line of political oncologists,” delivered the keynote address at the Oncology Nursing Society annual meeting in 1990, she set forth bold predictions for the ensuing 20 years of the field: appointments conducted over “computerphone,” major genetic breakthroughs, and universal healthcare.
Emma Lee Wen knows exactly what science can accomplish.
The definition of “therapeutic imperative” is this: A treatment necessity that must be met in order to prevent death. Once the imperative is clearly defined, addressing it properly links correct diagnosis with therapy and favorable prognosis. On the other hand, misdiagnosis or inadequate diagnosis fails to provide a framework for highly effective or curative therapy.
This year, Fred Hutch Cancer Center celebrates its 50th anniversary. Fred Hutch will be marking this milestone with a series of historical articles, a timeline, photo archives, and more as the year progresses.
The University of New England recently signed its first intellectual property license agreement with Satya Diagnostics—a company that recently received $100,000 in MaineHealth Bonfire Funding to help it achieve its goal of improving cancer detection and treatment in communities across the world.
Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president
Patrizia Cavazzoni will rejoin Pfizer Inc. as chief medical officer and executive vice president.
Jenny Chang, a cancer clinician-scientist, was named executive vice president, president and CEO, and chief academic officer of the Houston Methodist Academic Institute.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research.
